Our previous work clearly demonstrates blockade of MyD88 signaling with our novel Myd88 inhibitor, TJ-M2010-5, profoundly relieves colitis and tumor growth in the AOM/DSS-induced CAC mouse model9. This evidence concerns the gene MYD88 and colitis.